Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1Breast Diseases 1

Interventions

Fulvestrant 81Letrozole 74Paclitaxel 71pembrolizumab 67Specimen Handling 63Trastuzumab 60Carboplatin 55Magnetic Resonance Spectroscopy 50ribociclib 47Capecitabine 47Anastrozole 45palbociclib 44pertuzumab 43Tamoxifen 38Cyclophosphamide 38exemestane 37abemaciclib 37Biopsy 35trastuzumab deruxtecan 30Docetaxel 28Taxes 27Gemcitabine 25Radiotherapy 24Surveys and Questionnaires 23130-nm albumin-bound paclitaxel 23Standard of Care 21Blood Specimen Collection 21sacituzumab govitecan 20olaparib 20eribulin 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leflunomide × Breast × 90 days × Clear all
NCT03709446 2026-03-19

Leflunomide in Previously Treated Metastatic Triple Negative Cancers

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
17 enrolled
Breast

Breast Diseases, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡